Horizon Pharma (HZNP) Stock Gains on Raised Guidance
NEW YORK (TheStreet) -- Horizon Pharma (HZNP - Get Report) stock is up by 6.14% to $19.20 in mid-morning trading on Tuesday, after the company raised its full-year 2016 revenue guidance.
The Irish biopharmaceutical company announced on Tuesday that it expects full-year revenue of $1.03 to $1.05 billion, versus its previous projection for revenue between $950 million and $975 million for the year.
Horizon raised its revenue guidance as its acquisition of Crealta Holdings is expected to close this week, the company said in a statement.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.